Phase 2
Completed N=106
Phase IIA Study in Patients With Schizophrenia
Source: ClinicalTrials.gov NCT00686998 ↗Enrolled (actual)
106
Serious AEs
5.7%
Results posted
Jun 2011
Primary outcomePrimary: Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline — 1.40; 4.51; -8.79 Points on a scale
Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive and Negative Syndrome Scale (PANSS) Total Score Change From Baseline |
1.40; 4.51; -8.79 | — |
Eligibility Criteria
Inclusion Criteria
- Females of non-childbearing potential
- Diagnosis of Schizophrenia
Exclusion Criteria
- Clinically relevant disease and /or abnormalities.
- Alcohol or substance abuse not in remission
- Enrollment in another investigational study within 30 days
Data sourced from ClinicalTrials.gov (NCT00686998). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.